Clinical trials · Tennessee
Carcinoma clinical trials in Tennessee
We’re tracking 196 recruiting carcinoma studies with a site in Tennessee — including Early Phase 1, Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.
Recruiting studies in Tennessee
- NCT05799144RecruitingPhase 2
Pembrolizumab plus investigational HPV drugs for throat cancer
This Phase 2 trial studies pembrolizumab (an immune therapy) combined with investigational treatment(s) pBI-11 and TA-HPV for advanced or recurrent oropharyngeal cancer that is HPV-positive and has certain immune marker levels (PD-L1 CPS ≥ 1). It may help your immune system better attack cancer.
Nashville, TennesseeAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Memphis, TennesseeAges Any age - NCT04585750RecruitingPhase 1/Phase 2
Study drug for TP53 Y220C-mutated advanced cancers
This early-phase study tests PC14586 (rezatapopt) in people with advanced or metastatic solid cancers that carry a specific TP53 mutation called Y220C. It mainly looks at safety and how well the treatment may work, sometimes combined with pembrolizumab.
Nashville, TennesseeAges 12 years+ - NCT05877599RecruitingPhase 1
Study of a new treatment for advanced cancers with a specific gene change
This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.
Nashville, TennesseeAges 18 years+ - NCT05361720RecruitingPhase 2
Genetic test to match treatment for advanced kidney cancer
This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.
Nashville, TennesseeAges 18 years+ - NCT05433142RecruitingPhase 1
XmAb 819 for advanced kidney cancer and other solid tumors
This Phase 1 trial tests a new drug called XmAb 819 to treat advanced clear cell kidney cancer and other cancers that have grown despite standard treatments. It mainly looks at safety and how the body responds, with the goal of finding signs the drug can work.
Nashville, TennesseeAges 18 years+ - NCT05468359RecruitingPhase 1/Phase 2
Testing four medicines in children and teens with hard-to-treat tumors
This early-phase trial studies how safe and effective a combination of four medicines is for children and teens with certain solid tumors that have come back or cannot be controlled with standard treatment. It may help by improving tumor control, while also carefully tracking side effects.
Germantown, TennesseeAges Up to 30 years - NCT05536141RecruitingPhase 1
Study of AB521 for kidney cancer and other solid tumors
This early-stage trial tests AB521, alone and in combination with other medicines, in people with advanced solid tumors—especially clear cell kidney cancer. It aims to find a safe dose and see whether the treatment could help shrink tumors or control the disease.
Nashville, TennesseeAges 18 years+ - NCT05669430RecruitingPhase 1/Phase 2
Testing an anti-cancer drug alone and with pembrolizumab
This early-phase study tests GV20-0251 (an anti-cancer treatment) by itself and combined with pembrolizumab, to see how well it works and how safe it is. It is for adults with advanced solid tumors that have grown despite standard treatments, or where standard treatments aren’t an option.
Nashville, TennesseeAges 18 years+ - NCT05691491RecruitingPhase 1/Phase 2
Temozolomide plus M1774 for advanced metastatic cancers
This Phase 1/2 trial tests a combination of temozolomide and M1774 to see how safe it is and whether it can help shrink advanced cancers that have spread. It focuses on certain tumor types and specific biomarker results, and it may be an option if standard treatments have been tried or aren’t possible.
Nashville, TennesseeAges 18 years+ - NCT05770531RecruitingPhase 2
Blood test guides chemo changes for metastatic breast cancer
This Phase 2 study uses a blood test that looks for “circulating tumor DNA” to help decide if standard chemotherapy should be changed. It aims to see whether this approach improves how well treatment works for certain metastatic (stage IV) breast cancers.
Nashville, TennesseeAges 18 years+ - NCT05803382RecruitingPhase 1
Adding a new drug to capecitabine for metastatic colorectal cancer
This Phase 1 study tests a new anti-cancer drug (ZEN003694) added to the usual chemotherapy capecitabine. It is for adults with colorectal cancer (and possibly other cancers) that has spread or cannot be removed and has continued despite prior standard treatment.
Nashville, TennesseeAges 18 years+ - NCT05901545RecruitingPhase 1
Test an iodine-labeled drug to map neck lymph nodes
This Phase 1 study tests a labelling of panitumumab with iodine (111In) to see how well it can identify lymph nodes in head and neck cancer before surgery. The goal is to improve lymph node staging (which can help guide treatment), with the main focus on safety and early performance.
Nashville, TennesseeAges 19 years+ - NCT05945875RecruitingPhase 1
Dual scans to find head and neck cancer spread
This early-stage study tests two different imaging (scanning) methods to better detect head and neck cancer. Your results from the scans may help doctors see where disease is before standard surgery to remove lymph nodes in the neck.
Nashville, TennesseeAges 19 years+ - NCT06163534Recruiting
Biomarker profiling study for advanced head and neck cancer patients
This study collects blood and tumor tissue samples to analyze biological markers in patients with advanced head and neck squamous cell carcinoma before starting immunotherapy. The goal is to better understand how these markers relate to treatment response.
Nashville, TennesseeAges 18 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Nashville, TennesseeAges 18 years+ - NCT06174428Recruiting
Study of a new oral and throat cancer test
This study is testing a new, simple test that looks for signs of oral or throat cancer. If you have a suspicious spot or symptom, this test might help find out if it's cancer.
Memphis, TennesseeAges 18 years+ - NCT06183268Recruiting
Proton therapy for head and neck cancer skin side effects
This study looks at how proton therapy affects skin in people with head and neck cancer. It aims to better understand and manage skin reactions during treatment.
Knoxville, TennesseeAges 18 years+ - NCT06234605RecruitingPhase 1
Study of a new combination for advanced kidney cancer
This trial tests an experimental drug (HC-7366) combined with an approved targeted therapy (belzutifan) for people with advanced kidney cancer. It aims to see if the combination is safe and works better than either drug alone.
Nashville, TennesseeAges 18 years+ - NCT07049926RecruitingPhase 1/Phase 2
Combination therapy study for advanced kidney cancer
This trial tests new drug combinations for people with advanced kidney cancer whose disease returned after a prior immunotherapy. It's designed to find better treatment options for those who have not received other treatments for advanced disease.
Nashville, TennesseeAges 18–120 - NCT06475937RecruitingPhase 1
DM001 for advanced solid tumors study
This study tests an experimental drug called DM001 for people with certain advanced cancers (breast, lung, stomach, gastroesophageal, or colorectal) that have not responded to or are not helped by standard treatments. The goal is to see if the drug is safe and how it affects the tumors.
Nashville, TennesseeAges 18 years+ - NCT06708949RecruitingPhase 2
Immunotherapy combo for advanced kidney cancer
This trial compares two immunotherapy combinations—nivolumab/relatlimab/ipilimumab vs. nivolumab/ipilimumab—as first treatment for advanced kidney cancer with clear cell features. It aims to see which combo works better for people who haven't had prior therapy.
Nashville, TennesseeAges 18 years+ - NCT06828588RecruitingEarly Phase 1
A new imaging test for people on HER2 cancer therapy
This study tests a new imaging drug called [68Ga]Ga-ABY-025 to see how well it shows HER2-positive tumors in people who are about to start or have just started HER2-targeted cancer therapy. It may help doctors see if the treatment is working.
Nashville, TennesseeAges 18 years+ - NCT06906562RecruitingPhase 2
Pemigatinib for advanced pancreatic cancer with FGFR changes
This trial tests a targeted pill, pemigatinib, for people with advanced pancreatic cancer that has a specific FGFR gene change. The study is done entirely through telemedicine, so you can participate from home if eligible.
Knoxville, TennesseeAges 18 years+
Where these studies are running in Tennessee
Institutions with a site for the recruiting carcinoma studies listed above.
- Vanderbilt University Medical Center · 11 studies
- Research Site · 2 studies
- Sarah Cannon Research Institute · 2 studies
- SCRI Oncology Partners · 2 studies
- Massive Bio SYNERGY-AI site
- Methodist Le Bonheur Healthcare
- Ohio State University Telemedicine
- Ohio State University-Telemedicine
What taking part in a carcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Carcinoma trials in other states
Common questions
- Are there carcinoma clinical trials in Tennessee?
- Yes. We're currently tracking 196 recruiting carcinoma studies with a site in Tennessee, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a carcinoma study in Tennessee?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Tennessee to take part?
- Not necessarily. These studies have a site in Tennessee, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a carcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New carcinoma studies open in Tennessee regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.